FOLD
Amicus Therapeutics Inc

6,328
Loading...
Loading...
News
all
press releases
Earnings Estimates Moving Higher for Amicus Therapeutics (FOLD): Time to Buy?
Amicus Therapeutics (FOLD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks·1mo ago
News Placeholder
More News
News Placeholder
Does Amicus Therapeutics (FOLD) Have the Potential to Rally 138.21% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 138.2% in Amicus Therapeutics (FOLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·1mo ago
News Placeholder
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Amicus misses second-quarter earnings estimates but beats the same for revenues, driven by strong sales of Galafold and Pombiliti + Opfolda.
Zacks·1mo ago
News Placeholder
Amicus Therapeutics (FOLD) Misses Q2 Earnings Estimates
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -50.00% and +4.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Moderna (MRNA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·1mo ago
News Placeholder
Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·1mo ago
News Placeholder
New Strong Sell Stocks for June 3rd
Zacks·3mo ago
News Placeholder
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Shareholders to Contact the Firm
Kaskela Law LLC announces that it is investigating Amicus Therapeutics, Inc. (NASDAQ: FOLD) (Amicus) on behalf of the companys shareholders. Click here for additional information...
Business Wire·7mo ago
News Placeholder
The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts
Latest Ratings for FOLD DateFirmActionFromTo Feb 2022SVB LeerinkMaintainsOutperform Jan 2022SVB LeerinkUpgradesMarket PerformOutperform Jan 2022Cantor FitzgeraldMaintainsOverweight View More...
Benzinga·10mo ago
News Placeholder
Peeling Back The Layers: Exploring Amicus Therapeutics Through Analyst Insights
Latest Ratings for FOLD DateFirmActionFromTo Feb 2022SVB LeerinkMaintainsOutperform Jan 2022SVB LeerinkUpgradesMarket PerformOutperform Jan 2022Cantor FitzgeraldMaintainsOverweight View More...
Benzinga·10mo ago

Latest FOLD News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.